Treanda
Links shared publicly online about this topic
Treanda (bendamustine HCL): Recall - Particulate Matter in Vial
fda.gov — “Potential adverse events after intravenous administration of solutions containing particulates may include emboli and result in disruption of blood flow, causing tissue/organ damage.” View full resource at fda.gov
Most Recently Shared on January 30, 2012 at 3:14 pm By:
Feds probe Cephalon's Treanda marketing - FiercePharma
fiercepharma.com — “Yet another drugmaker finds itself under the U.S. Justice Department microscope. As Pharmalot reports, Cephalon ($CEPH) has received some requests from the feds for documents relating to potential Read more...” View full resource at fiercepharma.com
Most Recently Shared on July 12, 2011 at 4:35 pm By:
Feds probe Cephalon's Treanda marketing. http://bit.ly/qRmSvK
MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone
news-medical.net — “The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), ” View full resource at news-medical.net
Most Recently Shared on April 7, 2010 at 5:51 am By:
MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone: The Multiple Myeloma R... http://bit.ly/9BO9sV
Drug Sales In The Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche And Cephalon
medicalnewstoday.com — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelo” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 6:05 pm By:
Drug Sales In The Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche ... http://mnt.to/3KhD
Medical News: ASH: New Combo Challenges Standard Treatment for Indolent Lymphomas - in Meeting Coverage, ASH: Hematology from MedPage Today
medpagetoday.com — “NEW ORLEANS -- Bendamustine (Treanda) could replace the so-called CHOP regimen as the optimal partner with rituximab as the standard first-line treatment for indolent and mantle cell lymphomas, resear” View full resource at medpagetoday.com
Most Recently Shared on December 6, 2009 at 5:29 am By:
ASH: New Combo Challenges Standard Treatment for Indolent Lymphomas (CME/CE) http://ow.ly/1671Wn
Cephalon | News Releases
cephalon.com — “put page description here” View full resource at cephalon.com
Most Recently Shared on November 5, 2009 at 4:29 pm By:
eyeonfda Pharma and Health Lawyer
Cephalon Data on TREANDA Responses in Relapsed Indolent Non-Hodgkin's Lymphoma - http://ow.ly/zzYm
NICE refuses cancer drugs Arzerra, Torisel and Levact | InPharm
inpharm.com — “NICE refuses cancer drugs Arzerra, Torisel and Levact | InPharm” View full resource at inpharm.com
Most Recently Shared on October 27, 2010 at 11:05 am By:
Pharmafocus Health News and Pharma
NICE refuses cancer drugs Arzerra, Torisel and Treanda http://ht.ly/306Qq
PharmaTelevision - PTV News: Dec 7, 2009
pharmatelevision.com — “PharmaTelevision - PTV News: Dec 7, 2009” View full resource at pharmatelevision.com
Most Recently Shared on December 7, 2009 at 5:40 pm By:
Top stories on December 7th, 2009: Treanda triumph: Data gives Cephalon blockbuster hopes Novartis celebrates... http://tinyurl.com/yaahbf2
P2 TV
patientpower.info — “Patient power® - medical information and resources.” View full resource at patientpower.info
Most Recently Shared on January 19, 2010 at 6:25 pm By:
VIDEO -- Also from the ASH conference re: follicular NHL. Bendamustine + Rituxan (MabThera) vs CHOP +R. http://bit.ly/5LTxwx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Dawn McKinney, MS/RN
RN/Nursing Educator; consultant. Interests include peds neuro & psych, including genetics. Former Navy LCDR with varied acute care experience.
-
FiercePharma
FiercePharma's 140. Join 50,000 pharma insiders on our free newsletter at FiercePharma.com
-
News-Medical.Net
Medical News from Around the World
Advertisement
